Exploring the Effectiveness of Group Cognitive Stimulation Therapy in People With Schizophrenia.
NCT ID: NCT04916483
Last Updated: 2021-06-07
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
NA
90 participants
INTERVENTIONAL
2021-01-15
2021-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Objective: The purpose of this study is to explore the efficacy of group cognitive stimulation therapy in cognitive function, depressive symptoms, social function, and quality of life in people with Schizophrenia.
Research method:This study used a single-blind randomized controlled trial design. Participants's Montreal Cognitive Assessment Scale (MoCA) score between 10-25 points are include. Chronic rehabilitation wards were randomly assigned to the experimental group and the conventional treatment group using blocking. The experimental group (EG) (n = 45) is receive 7 weeks, twice a week, 60 minutes each time of group cognitive stimulation therapy(GCST), the control group (CG) (n = 45) maintain usual care.
Expected results: GCST can improve cognitive function, depressive symptoms, social function and quality of life in people with schizophrenia.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
The Evaluation of Therapeutic Efficacy on the Integrated Group Psychotherapy for Patients With Schizophrenia
NCT01139099
Compensatory Cognitive Training For Schizophrenia
NCT04040998
Effects of Narrative Enhancement and Cognitive Therapy (NECT) on Self-stigma in Patients With Schizophrenia
NCT03967431
Exploring the Effect of Rumination-Focused Cognitive Behaviour Therapy in Patients With Schizophrenia
NCT04442893
Exploring the Effectiveness of Digital Anti-stigma Therapy on Illness Perception and Perceived Stigma in Patients With Schizophrenia and Their Primary Caregivers
NCT06563752
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Objective: The purpose of this study explores the efficacy of group cognitive stimulation therapy in cognitive function, depressive symptoms, social function and quality of life in people with Schizophrenia.
Research method: This study used a single-blind randomized controlled trial design to reduce it to people with schizophrenia.This study used a single-blind randomized controlled trial design. Participants's Montreal Cognitive Assessment Scale (MoCA) score between 10-25 points are include. Chronic rehabilitation wards were randomly assigned to the EG and the CG using blocking. The EG receive 7 weeks, twice a week, 60 minutes each time of GCST, the CG maintain usual care. Both groups use the Montreal Cognitive Assessment Scale (MoCA), the Taiwanese Version of Frontal Assessment Battery (TFAB), the Beck Depression Inventory II (Beck Depression Inventory II, BDI-II), and Social Function Scales-Taiwanese version(SFST) and WHOQOL-BREF is use as an evaluation tool to measure the results at the baseline, T1 (7th weeks) and T2 (20th weeks). The research results were filed and statistically analyzed with IBM SPSS 20.0 software package. Descriptive statistics were used for general demographic variables and primary , secondary outcome: mean, SD, range, percentage. The difference between the two groups of benchmark values was analyzed with t-test or χ2, independent-t test, pair-t, and GEE.
Expected results: GCST can improve cognitive function, depressive symptoms, social function and quality of life in people with schizophrenia.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Exploring the effectiveness of GCST in people with schizophrenia.
The experimental group will receive a total of 14 sessions, twice a week group cognitive stimulation therapy for 7 weeks.
group cognitive stimulation therapy
The experimental group will receive totally 7 weeks,14 sessions, twice a week, and 60 minute group cognitive stimulation therapy (GCST).
usual care
The control group maintains the unit routine treatment.
Control group
The control group maintains the usual care.
No interventions assigned to this group
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
group cognitive stimulation therapy
The experimental group will receive totally 7 weeks,14 sessions, twice a week, and 60 minute group cognitive stimulation therapy (GCST).
usual care
The control group maintains the unit routine treatment.
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Age between 20 and 65 years old.
3. There are currently rules for receiving antipsychotics treatment.
4. Regardless of whether you take antidepressants or not.
5. Can communicate clearly in Mandarin and Taiwanese.
6. Those with a score of 10-25 on the Montreal Cognitive Assessment Scale (MoCA).
7. Those who are willing to participate in this study and complete the subject consent form.
Exclusion Criteria
2. Have been in or out of the acute ward within three months and currently have suicidal attempts or violence.
3. Those who are receiving individual or group cognitive behavior therapy.
4. People with intellectual disabilities.
5. Those who are unable to conduct research due to visual or hearing impairment.
6. People who are accepting other clinical trials.
7. Those who have no intention to participate in this study or are unable to complete the subject's consent form.
20 Years
65 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
National Yang Ming Chiao Tung University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Chiu-Yueh Yang
Professor
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Chiu-Yueh Yang, PhD
Role: PRINCIPAL_INVESTIGATOR
National Yang-Ming Jiaotong University
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
National Yang-Ming Jiaotong University
Taipei, , Taiwan
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
IRB1081209-04
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.